These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30386917)

  • 21. Prognostic impact of early treatment with tolvaptan in patients with acute heart failure and renal dysfunction.
    Matsue Y; Suzuki M; Torii S; Yamaguchi S; Fukamizu S; Ono Y; Fujii H; Kitai T; Nishioka T; Sugi K; Onishi Y; Noda M; Kagiyama N; Satoh Y; Yoshida K; Goldsmith SR
    Int J Cardiol; 2016 Oct; 221():188-93. PubMed ID: 27404673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship Between Serum Sodium Level Within the Low-Normal Range on Admission and Long-Term Clinical Outcomes in Patients with Acute Decompensated Heart Failure.
    Hiki M; Kasai T; Yatsu S; Murata A; Matsumoto H; Kato T; Suda S; Miyazaki T; Takagi A; Daida H
    Int Heart J; 2018 Sep; 59(5):1052-1058. PubMed ID: 30101847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of two dosing methods for immediate administration of tolvaptan in acute decompensated heart failure.
    Oguri M; Ishii H; Ohguchi S; Takahara K; Kawamura Y; Yokoi Y; Izumi K; Takahashi H; Kamiya H; Murohara T
    J Cardiol; 2018 Sep; 72(3):234-239. PubMed ID: 29566934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term administration of Tolvaptan to patients with decompensated cirrhosis.
    Kanayama K; Chiba T; Kobayashi K; Koroki K; Maruta S; Kanzaki H; Kusakabe Y; Saito T; Kiyono S; Nakamura M; Ogasawara S; Suzuki E; Ooka Y; Nakamoto S; Yasui S; Kanda T; Maruyama H; Kato J; Kato N
    Int J Med Sci; 2020; 17(7):874-880. PubMed ID: 32308540
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of tolvaptan add-on therapy in patients with acute heart failure: meta-analysis on randomised controlled trials.
    Ma G; Ma X; Wang G; Teng W; Hui X
    BMJ Open; 2019 May; 9(4):e025537. PubMed ID: 31048435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of the early use of V2 receptor antagonists in elderly patients with decompensated heart failure.
    Matsukawa R; Kubota T; Okabe M; Yamamoto Y; Meno H
    Heart Vessels; 2018 Feb; 33(2):145-154. PubMed ID: 28815407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of Urinary Sodium/Creatinine Ratio and Plasma Brain Natriuretic Peptide Level Predicts Successful Tolvaptan Therapy in Patients With Heart Failure and Volume Overload.
    Sato Y; Dohi K; Watanabe K; Tanimura M; Takeuchi T; Sugiura E; Sugimoto T; Kumagai N; Ogura T; Nakamori S; Fujimoto N; Yamada N; Ito M
    Int Heart J; 2016; 57(2):211-9. PubMed ID: 26973271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prognosis of patients with severely decompensated acute heart failure.
    Shirakabe A; Hata N; Yamamoto M; Kobayashi N; Shinada T; Tomita K; Tsurumi M; Matsushita M; Okazaki H; Yamamoto Y; Yokoyama S; Asai K; Shimizu W
    Circ J; 2014; 78(4):911-21. PubMed ID: 24553192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute Kidney Function Declines in the Context of Decongestion in Acute Decompensated Heart Failure.
    McCallum W; Tighiouart H; Testani JM; Griffin M; Konstam MA; Udelson JE; Sarnak MJ
    JACC Heart Fail; 2020 Jul; 8(7):537-547. PubMed ID: 32535124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early Commencement and Long-Term Continuation of Tolvaptan Treatment Attenuate Functional Impairment of Renal Vasopressin V2 Receptors and Improve Clinical Outcomes in Patients with Heart Failure.
    Noto T; Osanami A; Nagano N; Kokubu N; Kouzu H; Tanno M
    Int Heart J; 2023 Mar; 64(1):36-43. PubMed ID: 36725078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early use of V2 receptor antagonists is associated with a shorter hospital stay and reduction in in-hospital death in patients with decompensated heart failure.
    Matsukawa R; Kubota T; Okabe M; Yamamoto Y
    Heart Vessels; 2016 Oct; 31(10):1650-8. PubMed ID: 26676672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term effects and prognosis in acute heart failure treated with tolvaptan: the AVCMA trial.
    Suzuki S; Yoshihisa A; Yamaki T; Sugimoto K; Kunii H; Nakazato K; Abe Y; Saito T; Ohwada T; Suzuki H; Saitoh S; Kubota I; Takeishi Y
    Biomed Res Int; 2014; 2014():704289. PubMed ID: 25436213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The relationship between the time until commencement of tolvaptan and the length of hospital stay in heart failure patients.
    Kiuchi S; Hisatake S; Kabuki T; Oka T; Dobashi S; Fujii T; Ikeda T
    Heart Vessels; 2018 Apr; 33(4):367-373. PubMed ID: 29128961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Usefulness of the Direct and/or Total Bilirubin to Predict Adverse Outcomes in Patients With Acute Decompensated Heart Failure.
    Okada A; Sugano Y; Nagai T; Honda Y; Iwakami N; Nakano H; Takashio S; Honda S; Asaumi Y; Aiba T; Noguchi T; Kusano K; Yasuda S; Anzai T;
    Am J Cardiol; 2017 Jun; 119(12):2035-2041. PubMed ID: 28456315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolvaptan add-on therapy in patients with acute heart failure: A systematic review and meta-analysis.
    Luo X; Jin Q; Wu Y
    Pharmacol Res Perspect; 2020 Jun; 8(3):e00614. PubMed ID: 32500625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short-term effects of low-dose tolvaptan in acute decompensated heart failure patients with severe aortic stenosis: The LOHAS registry.
    Watanabe Y; Nara Y; Hioki H; Kawashima H; Kataoka A; Nakashima M; Nishihata Y; Hayashida K; Yamamoto M; Tanaka J; Mizutani K; Jujo K; Nakazawa G; Izumo M; Kozuma K
    Int J Cardiol; 2020 Apr; 305():82-86. PubMed ID: 32059993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of early ultrafiltration in patients with acute decompensated heart failure with volume overload: a prospective, randomized, controlled clinical trial.
    Hu J; Wan Q; Zhang Y; Zhou J; Li M; Jiang L; Yuan F
    BMC Cardiovasc Disord; 2020 Oct; 20(1):447. PubMed ID: 33054727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tolvaptan Reduces the Risk of Worsening Renal Function in Patients With Acute Decompensated Heart Failure and Preserved Left Ventricular Ejection Fraction　- Prospective Randomized Controlled Study.
    Tamaki S; Sato Y; Yamada T; Morita T; Furukawa Y; Iwasaki Y; Kawasaki M; Kikuchi A; Kondo T; Ozaki T; Seo M; Ikeda I; Fukuhara E; Abe M; Nakamura J; Fukunami M
    Circ J; 2017 Apr; 81(5):740-747. PubMed ID: 28202885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between C-reactive protein levels at hospital admission and long-term mortality in patients with acute decompensated heart failure.
    Matsumoto H; Kasai T; Sato A; Ishiwata S; Yatsu S; Shitara J; Murata A; Kato T; Suda S; Matsue Y; Hiki M; Takagi A; Daida H
    Heart Vessels; 2019 Dec; 34(12):1961-1968. PubMed ID: 31104078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitide.
    Suzuki S; Yoshihisa A; Yamaki T; Sugimoto K; Kunii H; Nakazato K; Abe Y; Saito T; Ohwada T; Suzuki H; Saitoh S; Kubota I; Takeishi Y;
    J Clin Pharmacol; 2013 Dec; 53(12):1277-85. PubMed ID: 24142853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.